A phase 1 trial of CUDC-907, an oral, first-in-class, dual inhibitor of HDAC and PI3K, in patients with refractory or relapsed lymphoma and multiple myeloma Meeting Abstract
| Authors: | Oki, Y.; Berdeja, J.; Patel, M.; Flinn, I.; Gerecitano, J.; Neelapu, S.; Copeland, A.; Akins, A.; Clancy, M.; Viner, J.; Wang, J.; Ma, A.; Younes, A. |
| Abstract Title: | A phase 1 trial of CUDC-907, an oral, first-in-class, dual inhibitor of HDAC and PI3K, in patients with refractory or relapsed lymphoma and multiple myeloma |
| Meeting Title: | 20th Congress of the European Hematology Association (EHA) |
| Journal Title: | Haematologica |
| Volume: | 100 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2015 Jun 11-14 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 0390-6078 |
| Publisher: | Ferrata Storti Foundation |
| Date Published: | 2015-06-01 |
| Start Page: | 109 |
| End Page: | 110 |
| Language: | English |
| ACCESSION: | WOS:000361204901231 |
| PROVIDER: | wos |
| PMCID: | PMC4480587 |
| Notes: | Meeting Abstract: P325 -- Source: Wos |
